Calliditas announces promising results for NOX enzyme inhibitor in rare liver disease
Calliditas Therapeutics has announced positive mid-stage results of its NOX enzyme inhibitor for a type of rare liver disease. The phase 2b TRANSFORM trial has been evaluating setanaxib in 76 patients with primary biliary cholangitis (PBC) and elevated …